Evidence map›Paper›PMID 27193336›Full record

ArticleZeitschrift fur Rheumatologie2016

[Severe therapy refractive osteoporosis : A rare differential diagnosis].

M Gehlen, A D Lazarescu, C Hinz, N Schmidt, M Pfeifer, M Werner, H F Weidemann, M Schwarz-Eywill, A Maier

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Zeitschrift fur Rheumatologie, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

M GehlenFachklinik für Rheumatologie, Orthopädie und Osteologie, Klinik Der FÜRSTENHOF, Osteologisches Schwerpunkt- und Forschungszentrum DVO, Am Hylligen Born 7, 31812, Bad Pyrmont, Deutschland. gehlen@staatsbad-pyrmont.de.
A D LazarescuFachklinik für Rheumatologie, Orthopädie und Osteologie, Klinik Der FÜRSTENHOF, Osteologisches Schwerpunkt- und Forschungszentrum DVO, Am Hylligen Born 7, 31812, Bad Pyrmont, Deutschland. lazarescu@staatsbad-pyrmont.de.
C HinzFachklinik für Rheumatologie, Orthopädie und Osteologie, Klinik Der FÜRSTENHOF, Osteologisches Schwerpunkt- und Forschungszentrum DVO, Am Hylligen Born 7, 31812, Bad Pyrmont, Deutschland.
N SchmidtFachklinik für Rheumatologie, Orthopädie und Osteologie, Klinik Der FÜRSTENHOF, Osteologisches Schwerpunkt- und Forschungszentrum DVO, Am Hylligen Born 7, 31812, Bad Pyrmont, Deutschland.
M PfeiferFachklinik für Rheumatologie, Orthopädie und Osteologie, Klinik Der FÜRSTENHOF, Osteologisches Schwerpunkt- und Forschungszentrum DVO, Am Hylligen Born 7, 31812, Bad Pyrmont, Deutschland.
M WernerHelios Klinikum Emil von Behring, Berlin, Deutschland.
H F WeidemannRheumatologische Facharztpraxis Joachimstraße, Hannover, Deutschland.
M Schwarz-EywillCampus Medizin, Evangelisches Krankenhaus, Universität Oldenburg, Oldenburg, Deutschland.
A MaierNordwestdeutsches Rheumazentrum, St.-Josef-Stift Sendenhorst, Sendenhorst, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic mastocytosis is defined as a clonal increase of mast cells. We report on four patients with severe osteoporosis and histologically confirmed systemic mastocytosis. In spite of antiresorptive therapy the patients developed further vertebral fractures and suffered from ostealgia. Systemic mastocytosis is an important differential diagnosis in patients with therapy refractive and unexplained osteoporosis. Skin involvement (urticaria pigmentosa) is a rare occurrence and in most cases an isolated involvement of bone marrow is present. Determination of serum tryptase can provide indications for systemic mastocytosis but the diagnosis is only confirmed by bone marrow biopsy. There is a high risk of vertebral fractures and patients should be treated in specialized centers. Zoledronic acid can be a therapeutic option for indolent osteoporosis associated with systemic mastocytosis.

Indexed as

AdultAnti-Inflammatory AgentsBone Density Conservation AgentsChronic DiseaseDiagnosis, DifferentialDiphosphonatesFemaleHumansImidazolesMaleMastocytosis, SystemicMiddle AgedOsteoporosisRare DiseasesTreatment FailureTreatment OutcomeAnti-Inflammatory AgentsBone Density Conservation AgentsDiphosphonatesImidazolesZoledronic AcidSystemic mastocytosisTherapy refractory osteoporosisUnexplained osteoporosisVertebral fracturesZoledronic acid

Identifiers

PMID27193336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.